It is noteworthy that approximately one fifth of the ESCC showed high expression of both VEGFR1 and VEGFR2, which further emphasizes the merit of targeting both VEGFR1 and VEGRF2 in the treatment of ESCC. This evidence concerns the gene KDR and esophageal squamous cell carcinoma.